Overview

Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart in the treatment of benign prostatic hyperplasia
Phase:
PHASE3
Details
Lead Sponsor:
Ache Laboratorios Farmaceuticos S.A.